Women account for over half the global population with HIV. Given the high rate of new infections, the implementation of female-controlled preventive methods is critical to successfully curb HIV. Toward this end, vaginal microbicides- topically applied, self-administered products that protect against HIV are being investigated. A primary risk factor for cervicovaginal HIV acquisition is bacterial vaginosis (BV). BV is characterized by overgrowth of anerobic bacteria and decrease in healthy vaginal lactobacilli and acidity. The compromised vaginal environment in women with BV significantly increases their susceptibility to HIV. Thus a microbicide aimed at preventing and treating BV is likely to be effective at HIV prophylaxis. The overall goal of this thesis is to develop and evaluate poly(ethylene) glycol (PEG) nanocarrier-based hydrogels for application as vaginal microbicides. The hydrogels are formed in situ by covalently cross-linking 8-arm PEG-SH and 4-arm PEG-NHS polymers via degradable thioester bonds. First, the vaginal coverage, distribution and retention of the hydrogels in mice were evaluated using MRI. Hydrogel volumes and surface contact were measured at various times post-dose and compared with hydroxyethylcellulose (HEC) gel. The hydrogels showed significantly longer vaginal retention (12-24 h) than HEC gel (2 h). In the second part of this thesis, PEG nanocarrier-based hydrogels for the controlled release of lactic acid were developed for maintaining vaginal acidity in women with BV. Nanocarrier-based hydrogels with covalently attached lactic acid showed sustained release (10-14% lactic acid) over several days, while hydrogels with passively entrapped lactic acid showed burst release (90% release within 30 min). Hydrogels with passively entrapped lactic acid inhibited the predominant BV pathogen Gardnerella vaginalis. The cytotoxicity of the polymers was also evaluated using vaginal epithelial cells. Finally, hydrogels for the controlled release of subtilosin, an antimicrobial peptide with activity against G. vaginalis was developed. Subtilosin release from the hydrogels was two-phase with initial rapid release (4 µg/hr for 12 h) followed by slow release (0.26 µg/hr from 12-120 h). Subtilosin-containing hydrogels inhibited G. vaginalis but did not significantly inhibit healthy vaginal lactobacilli spp. The antiviral activity of subtilosin against HIV was investigated and subtilosin weakly inhibited HIV replication (IC50= 5.8 µM).
Subject (authority = RUETD)
Topic
Biomedical Engineering
RelatedItem (type = host)
TitleInfo
Title
Rutgers University Electronic Theses and Dissertations
Rutgers University. Graduate School - New Brunswick
AssociatedObject
Type
License
Name
Author Agreement License
Detail
I hereby grant to the Rutgers University Libraries and to my school the non-exclusive right to archive, reproduce and distribute my thesis or dissertation, in whole or in part, and/or my abstract, in whole or in part, in and from an electronic format, subject to the release date subsequently stipulated in this submittal form and approved by my school. I represent and stipulate that the thesis or dissertation and its abstract are my original work, that they do not infringe or violate any rights of others, and that I make these grants as the sole owner of the rights to my thesis or dissertation and its abstract. I represent that I have obtained written permissions, when necessary, from the owner(s) of each third party copyrighted matter to be included in my thesis or dissertation and will supply copies of such upon request by my school. I acknowledge that RU ETD and my school will not distribute my thesis or dissertation or its abstract if, in their reasonable judgment, they believe all such rights have not been secured. I acknowledge that I retain ownership rights to the copyright of my work. I also retain the right to use all or part of this thesis or dissertation in future works, such as articles or books.